The role of vaccine therapy in the treatment of melanoma

Bibliography

• Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64(3):529-64
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future. Curr Opin Oncol 2007;19(2):121-7
   PubMed Web of Science ®Google Scholar
• Sabel MS, Sondak VK. Melanoma vaccines: breakthrough or bust? Cancer Investig 2002;20:1114-6
   PubMed Web of Science ®Google Scholar
• Jack A, Boyes C, Aydin N, Alam K, Wallack M. The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surg Oncol 2006;15(1):13-24
   PubMed Web of Science ®Google Scholar
• Komenaka I, Hoerig H, Kaufman HL. Immunotherapy for melanoma. Clin Dermatol 2004;22(3):251-65
   PubMed Web of Science ®Google Scholar
• Terando A, Sabel MS, Sondak VK. Melanoma: adjuvant therapy and other treatment options. Curr Treat Options Oncol 2003;4(3):187-99
   PubMedGoogle Scholar
• Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 2004;65(8):794-802
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67
   PubMed Web of Science ®Google Scholar
• Berd D, Kairys J, Dunton C, Mastrangelo MJ, Sato T, Maguire HC Jr. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 1998;25:646-53
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403-15
   PubMed Web of Science ®Google Scholar
• Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95(22):13141-6
   PubMed Web of Science ®Google Scholar
• Dillman RO, DePriest C, DeLeon C, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory Phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 2007;22(3):309-21
   PubMed Web of Science ®Google Scholar
• Lotem M, Peretz T, Drize O, et al. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer 2002;86(10):1534-9
   PubMed Web of Science ®Google Scholar
• Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines 2004;3(4):403-11
   PubMedGoogle Scholar
• Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002;20(20):4169-80
   PubMed Web of Science ®Google Scholar
• Pilla L, Patuzzo R, Rivoltini L, et al. A Phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients. Cancer Immunol Immunother 2006;55(8):958-68
   PubMed Web of Science ®Google Scholar
• Caudill MM, Li Z. HSPPC-96: a personalised cancer vaccine. Expert Opin Biol Ther 2001;1(3):539-47
   PubMed Web of Science ®Google Scholar
• Richards J, Testori A, Whitman E, et al. Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):8002
   Google Scholar
• Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82
   PubMed Web of Science ®Google Scholar
• Morton DL, Hsueh EC, Essner R, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002;236(4):438-48
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002;20(23):4549-54
   PubMed Web of Science ®Google Scholar
• Morton DL. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma. Dev Biol (Basel) 2004;116:209-17
   PubMedGoogle Scholar
• Sondak VK, Sosman JA. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®. Semin Cancer Biol 2003;13:409-41
   PubMed Web of Science ®Google Scholar
• Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 2006;12(7 Pt 2):2337s -2341s
   Google Scholar
• Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-93
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Harel W, Kempf RA, et al. Active specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-69
   PubMed Web of Science ®Google Scholar
• Elliott GT, McLeod RA, Perez J, Von Eschen KB. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 1993;2:41-53
   Google Scholar
• Mitchell MS, von Eschen KB. Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc Am Soc Clin Oncol 1997;16:494a
   Google Scholar
• Sondak VK, Liu P-Y, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. I. Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058-66
   PubMed Web of Science ®Google Scholar
• Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;20:2067-75
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69-77
   PubMed Web of Science ®Google Scholar
• Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:4181-90
   PubMed Web of Science ®Google Scholar
• Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137:1142-62
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol 2001;29(11):1247-55
   PubMed Web of Science ®Google Scholar
• Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: Current status and future directions. Vaccine 2007;25(Suppl 2):B4-16
   Google Scholar
• Zhang S, Wang Q, Miao B. Review: dendritic cell-based vaccine in the treatment of patients with advanced melanoma. Cancer Biother Radiopharm 2007;22(4):501-7
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17(4):563-70
   PubMed Web of Science ®Google Scholar
• Talebi T, Weber JS. Peptide vaccine trials for melanoma: preclinical background and clinical results. Semin Cancer Biol 2003;13(6):431-8
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Livingston PO. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2(4):205-11
   PubMedGoogle Scholar
• Parmiani G, Castelli C, Dalerba P, et al. Cancer immunothrapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94(11):805-18
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007;13(21):6386-95
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 2006;12(7 Pt 2):2331s-2336s
   Google Scholar
• Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7(7):1882-7
   PubMed Web of Science ®Google Scholar
• Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19(9):2370-80
   PubMed Web of Science ®Google Scholar
• Tang D, Devit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152-4
   PubMed Web of Science ®Google Scholar
• Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunisation. J Exp Med 1998;188:1075-82
   PubMed Web of Science ®Google Scholar
• Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999;189:169-78
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-84
   PubMed Web of Science ®Google Scholar
• Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21(12):2415-32
   PubMed Web of Science ®Google Scholar
• Wallack MK, Meyer M, Bourgoin A, et al. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. J Biol Res Mod 1983;2:586-96
   PubMedGoogle Scholar
• Kaufman HL, Cohen S, Cheung K, DeRaffele G, Mitcham J, Moroziewicz D, et al. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther 2006;17(2):239-44
   PubMed Web of Science ®Google Scholar
• Ramshaw IA, Ramsay AJ. The prime-boost strategy: Exciting prospects for improved vaccination. Immunol Today 2001;21:163-5
   Google Scholar
• Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med (Maywood) 2007;2329):1130-41
   PubMed Web of Science ®Google Scholar
• Weinschenk T, Gouttefangeas C, Schirle M, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002;62(20):5818-27
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Rivoltini L, et al. Immunotherapy of melanoma. Semin Cancer Biol 2003;13(6):391-400
   PubMed Web of Science ®Google Scholar
• Nawrocki S, Mackiewicz A. Clinical trials of active cancer immunotherapy. Expert Opin Investig Drugs 2007;16(8):1137-41
   PubMed Web of Science ®Google Scholar
• Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007;(8):1245-56
   PubMed Web of Science ®Google Scholar